EMJ Oncology 12 [Supplement 1] . 2024

This insightful article discusses the latest advancements in endometrial cancer research in 2023, including key data from renowned congresses throughout the year. The article highlights the unprecedented progression-free survival data from two Phase III randomised controlled trials evaluating first-line immunotherapy in combination with chemotherapy in patients with advanced or recurrent endometrial cancer: RUBY with dostarlimab, and NRG-GY018 with pembrolizumab, which created a buzz in March, and stimulated discussion throughout the remainder of the year. The overall survival results, clinically meaningful benefits regardless of mismatch repair status, and health-related quality of life in these studies are also discussed.